At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 43 enrolled
Drug / intervention
CGC-11047drug
Likely dose
CGC-11047 16.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib Randomized Open Label Study Between Once-every-two-weeks and Once-every-four-weeks Treatment of CGC-11047 in Patients With CNV Due to Age Related Macular Degeneration
In Brief
A Phase 1 clinical trial evaluating CGC-11047 for Age Related Macular Degeneration. Completed, enrolled 43 participants across 8 sites in 3 countries.
Detailed Summary
The purpose of this research study is to determine how safe and effective subconjunctival injections of CGC-11047 are in subjects with wet age related macular degeneration at two different dosing intervals.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge Related Macular Degeneration
CountriesMexico, Russia, United States
Collaborators--
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartApr 2007
Primary CompletionOct 2007
TodayJul 2026
First PostedMar 13, 2007
Enrollment StartApr 1, 2007
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 19.3 years ago
Interventions
CGC-11047drug
16.5 mg (3.3%) subconjunctival injection